Argue an international band of leading medical academics.

They think that academic medicine is failing to carry out its key functions of research, teaching, and patient treatment, and have developed an idea of action to tackle these nagging problems. We are in need of a new vision for academic medication, they write. We have to articulate and demonstrate the financial and social worth that academic medication provides. And we need a global perspective. Others query how academic medicine handles gender issues. Researchers in the United States argue that improving gender equity instead of gender equality is vital for a revitalised educational medicine, a strengthened wellness workforce, and improved open public wellness. Canadian doctors discuss conflicts involving academic independence, while two editorials highlight how academic medicine can help improve health in developing countries.The first FORWARD research, analyzing the onset of clinical effect, safety and tolerability of ALKS 5461 in approximately 60 patients with MDD, has begun, and the three primary efficacy studies are anticipated to begin with in mid 2014. Alkermes expects to use security and efficacy data from the Forwards studies as the basis for a New Drug Software to become submitted to the U.S. Food and Medication Administration , pending research outcomes. With a novel system of actions and Fast Monitor designation from the FDA, ALKS 5461 is designed to provide a new treatment choice for the millions of people with MDD with urgent unmet medical requirements, mentioned Elliot Ehrich, M.D., Chief Medical Officer of Alkermes.